{"id":"nct:NCT07754045","kind":"trial","title":"Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults","authors":["Lumos Pharma"],"author_count":1,"year":2026,"published":"2026-08-10","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07754045","source_url":"https://clinicaltrials.gov/study/NCT07754045","archive_url":"https://space-kitty.com/papers/nct:NCT07754045","updated":"2026-08-10","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\\^2, between the ages of 60 and 85 years that have mild functional impairment.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Obesity & Overweight"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":202,"sponsor":"Lumos Pharma","conditions":["Obesity & Overweight"],"interventions":["DRUG: LUM-201","DRUG: Placebo","DRUG: Semagludtide"],"start_date":"2027-02-15","start_date_type":"ESTIMATED","primary_completion_date":"2028-02-15","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}